Eligi
Med
Base de datos
Seguridad
Sobre EligiMed
Contacto
Contáctenos
Ensayos Clínicos de Endocrinología | EligiMed
Ensayos clínicos
694 ensayos encontrados
Desconocido
ClinicalTrials.gov
Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome
OBSERVATIONAL
Inicio: 1 de dic de 2007
ID: NCT00784615
Completado
Fase 3
ClinicalTrials.gov
A 24-week, Multicentre, Randomised, Double-blind, Age-stratified, Placebo Controlled, Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Pts With T2DM, CV Disease and Hypertension Who Exhibit Inadequate Glycaemic Control on Usual Care
INTERVENTIONAL
Inicio: 1 de feb de 2010
ID: NCT01031680
Retirado
ClinicalTrials.gov
Cost-effectiveness Pharmacoeconomic Study of a Standardized Multidisciplinary Weight Loss Method (PronoKal® Method) to Improve the Health Condition of Obese Patients With Associated Comorbidities
OBSERVATIONAL
Inicio: 1 de may de 2018
ID: NCT05833464
Completado
Fase 3
ClinicalTrials.gov
A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naive Patients With Type 2 Diabetes Mellitus: A Double-Blind, Randomized Study
INTERVENTIONAL
Inicio: 1 de nov de 2011
ID: NCT01435616
Completado
ClinicalTrials.gov
Programme of Diabetes Education in the City of Corrientes (PRODIACOR): Clinical, Metabolic and Economic Outcomes of a Prospective-randomized Trial Based on Different Patient-centered Educational Strategies for People With Type 2 Diabetes
INTERVENTIONAL
Inicio: 1 de dic de 2006
ID: NCT01456806
Terminado
Fase 2
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
INTERVENTIONAL
Inicio: 25 de jul de 2017
ID: NCT03152552
Completado
Fase 3
ClinicalTrials.gov
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
INTERVENTIONAL
Inicio: 30 de nov de 2016
ID: NCT02941926
Terminado
Fase 2
ClinicalTrials.gov
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin
INTERVENTIONAL
Inicio: 1 de sept de 2009
ID: NCT00958841
Completado
ClinicalTrials.gov
Analysis of the Pre- and Post-prandial Levels of Appetite Regulatory Hormones in Adult Individuals
INTERVENTIONAL
Inicio: 1 de sept de 2021
ID: NCT05815641
Completado
ClinicalTrials.gov
Biological Effects in Consumers of Resveratrol-enriched Wine
OBSERVATIONAL
Inicio: 15 de jul de 2022
ID: NCT05981053
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
INTERVENTIONAL
Inicio: 19 de oct de 2020
ID: NCT04537923
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Open-Label, Parallel-Group Study to Compare Two Dosing Algorithms for Preprandial Human Insulin Inhalation Powder (HIIP) in Insulin-Naive Patients With Type 2 Diabetes Mellitus
INTERVENTIONAL
Inicio: 1 de oct de 2006
ID: NCT00391209
Completado
Fase 3
ClinicalTrials.gov
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor
INTERVENTIONAL
Inicio: 27 de sept de 2023
ID: NCT06065540
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS477118) in Combination With Thiazolidinedione Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone
INTERVENTIONAL
Inicio: 1 de mar de 2006
ID: NCT00295633
Completado
Fase 4
ClinicalTrials.gov
A Randomised, Parallel-group, Open-label, Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen, in the Treatment of Pregnant Women With Type 1 Diabetes, Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes
INTERVENTIONAL
Inicio: 1 de sept de 2002
ID: NCT00365170
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Thiazolidinedione Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone
INTERVENTIONAL
Inicio: 1 de jul de 2008
ID: NCT00683878
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Response, Multicentre, Multinational Study Evaluating the Efficacy and Safety of AVE2268 Administered Either Twice Daily (Breakfast and Lunch) at a Dose of 300, 600 and 1200 mg or Once Daily (Breakfast) at a Dose of 1200 mg, in Patients With Type 2 Diabetes Treated With Metformin and Not Adequately Controlled
INTERVENTIONAL
Inicio: 1 de jul de 2006
ID: NCT00361738
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study Evaluating the Efficacy and Safety of Four Doses of SR147778 in Obese Patients
INTERVENTIONAL
Inicio: 1 de nov de 2004
ID: NCT00239174
Completado
Fase 3
ClinicalTrials.gov
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of Linagliptin (5 mg), Administered Orally Once Daily for at Least 52 Weeks in Type 2 Diabetic Patients in Combination With Basal Insulin Therapy
INTERVENTIONAL
Inicio: 1 de ago de 2009
ID: NCT00954447
Terminado
Fase 3
ClinicalTrials.gov
A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 In The Treatment Of Obese Subjects
INTERVENTIONAL
Inicio: 1 de feb de 2007
ID: NCT00396448
Anterior
1
...
23
24
25
...
35
Siguiente
Filtros